{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-269833","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.267264+00:00","generated_at":"2026-05-16T23:33:59.990444+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sutro Biopharma Q3 revenue $9.7M, cash $167.6M; IND cleared for STRO-004","bullets":["FDA cleared IND for STRO-004 (Tissue Factor ADC); first patient dosing expected before year-end.","Cash, cash equivalents and marketable securities were $167.6M at Sept. 30, 2025, down from $388.3M a year earlier.","Revenue was $9.7M (vs $8.5M Q3 2024), primarily from Astellas collaboration.","R&D and G&A expenses totaled $48.6M, down from $76.4M in Q3 2024.","Organizational restructuring expected to extend cash runway into at least mid-2027; restructuring costs estimated at $4.1M–$4.3M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-269833","json":"https://secwatch.observer/filing/0001193125-25-269833.json","markdown":"https://secwatch.observer/filing/0001193125-25-269833.md","text":"https://secwatch.observer/filing/0001193125-25-269833.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000119312525269833/0001193125-25-269833-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000119312525269833/stro-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:33:59.990444+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}